CA2406277A1 - Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof - Google Patents

Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof Download PDF

Info

Publication number
CA2406277A1
CA2406277A1 CA002406277A CA2406277A CA2406277A1 CA 2406277 A1 CA2406277 A1 CA 2406277A1 CA 002406277 A CA002406277 A CA 002406277A CA 2406277 A CA2406277 A CA 2406277A CA 2406277 A1 CA2406277 A1 CA 2406277A1
Authority
CA
Canada
Prior art keywords
accordance
drug delivery
delivery system
sustained release
impermeable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002406277A
Other languages
French (fr)
Other versions
CA2406277C (en
Inventor
Hong Guo
Paul Ashton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyepoint Pharmaceuticals US Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2406277A1 publication Critical patent/CA2406277A1/en
Application granted granted Critical
Publication of CA2406277C publication Critical patent/CA2406277C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T29/00—Metal working
    • Y10T29/49—Method of mechanical manufacture
    • Y10T29/49826—Assembling or joining
    • Y10T29/49888—Subsequently coating

Abstract

A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of a n effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir including the effective agent, an impermeable tube which encloses portions of the reservoir, and a permeable member at an end of the tube.</SD OAB>

Claims (40)

1. ~A sustained release drug delivery system comprising:
an inner drug core comprising a therapeutically effective amount of an agent effective in obtaining a desired local or systemic physiological or pharmacological effect;
an inner tube impermeable to the passage of said agent, said inner tube having first and second ends and covering at least a portion of said inner drug core, said inner tube sized and formed of a material so that said inner tube is dimensionally stable to accept said drug core without changing shape;
an impermeable member positioned at said inner tube first end, said impermeable member preventing passage of said agent out of said drug core through said inner tube first end; and a permeable member positioned at said inner tube second end, said permeable member allowing diffusion of said agent out of said drug core through said inner tube second end.
2. A sustained release drug delivery system in accordance with Claim 1, wherein said inner tube is a polymer or a metal.
3. A sustained release drug delivery system in accordance with Claim 1, wherein said impermeable member comprises an impermeable cap abutting said inner tube first end.
4. A sustained release drug delivery system in accordance with Claim 1, further comprising a permeable outer layer surrounding said inner tube, and wherein said permeable member comprises a portion of said permeable outer layer.
5. A sustained release drug delivery system in accordance with Claim 4, further comprising a hole through said impermeable inner tube communicating said drug core with said permeable outer layer.
6. A sustained release drug delivery system in accordance with Claim 1, further comprising an impermeable outer layer surrounding said inner tube, and wherein said impermeable member comprises a portion of said impermeable outer layer.
7. A sustained release drug delivery system in accordance with Claim 6, wherein said permeable member comprises a permeable plug abutting said inner tube second end.
8. A sustained release drug delivery system in accordance with Claim 7, wherein said permeable plug has a radial exterior surface and an end surface opposite said drug core, and said impermeable outer layer covers at least part of said radial.
exterior surface and at least a part of said plug end surface.
9. A sustained release drug delivery system in accordance with Claim 7, further comprising a port in said impermeable outer layer positioned to allow agent to diffuse out of said drug core, through said plug, through said port, and out of said device.
10. A sustained release drug delivery system in accordance with Claim 9, wherein said port is formed in said impermeable outer layer immediately adjacent to a surface of said plug selected from the group consisting of said plug end surface, said plug radial surface, and both.
11. A sustained release drug delivery system in accordance with Claim 9, wherein said port is formed in said impermeable outer layer immediately adjacent said plug radial surface, and wherein said port comprises a plurality of openings formed in said impermeable outer layer immediately adjacent said plug radial surface.
12. A sustained release drug delivery system in accordance with Claim 6, wherein said impermeable outer layer extends along and covers said plug radial surface and terminates at said plug end surface.
13. A sustained release drug delivery system in accordance with Claim 1, wherein said effective agent is fluocinolone acetonide.
14. A sustained release drug delivery system in accordance with Claim 1, wherein said effective agent is nimodipine.
15. A sustained release drug delivery system in accordance with Claim l, wherein said effective agent is a steroid.
16. A sustained release drug delivery system in accordance with Claim 1, wherein said effective agent is a neuroprotectant.
17. A sustained release drug delivery system in accordance with Claim 1, wherein said impermeable inner tube is formed of a material which impedes the passage of eroding agents into said inner drug core when said system is exposed to said eroding agents.
18. A method for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect comprising:

administering the sustained release drug delivery system in accordance with Claim 1 to a mammalian organism in need of such treatment.
19. A method for treating a mammalian organism for ocular edema, ocular neovascularization, ocular edema, or ocular inflamation, comprising:
administering a sustained release drug delivery system in accordance with Claim 1 to a mammalian organism in need of such treatment, said drug delivery system drug core comprising a therapeutically effective amount of a steroid effective to obtain a desired local or systemic physiological or pharmacological effect.
20. A method in accordance with Claim 19, wherein said steroid is corticosteroid.
21. A method in accordance with Claim 20, wherein said corticosteroid is fluocinolone acetonide.
22. A method for providing controlled and sustained administration of an agent effective in obtaining a desired local or systemic physiological or pharmacological effect comprising:
inserting a sustained release drug delivery system in accordance with Claim 1 at a desired location.
23. A method in accordance with Claim 22, wherein said inserting step comprises injecting said system at a desired location.
24. A method in accordance with Claim 22, wherein said inserting step comprises surgically implanting said system at a desired location.
25. A method in accordance with Claim 22, wherein said inserting step comprises inserting said system in a location selected from the group consisting of the vitreous of the eye, under the retina, and onto the sclera.
26. A method in accordance with Claim 22, wherein said effective agent is a corticosteroid.
27. A method in accordance with Claim 26, wherein said corticosteroid is fluocinolone acetonide.
28. A method in accordance with Claim 22, wherein said effective agent is a neuroprotectant.
29. A method in accordance with Claim 28, wherein said neuroprotectant is nimodipine.
30. A method of manufacturing a sustained drug delivery system, comprising the steps of:
positioning a drug core in a tube, said drug core containing a therapeutically effective amount of an active agent; and positioning an end member to said tube to form a closed-end tube, said end member selected from the group consisting of an impermeable cap and a permeable plug.
31. A method in accordance with Claim 30, further comprising forming an outer layer around a portion of said tube, said outer layer formed of a material selected from the group consisting of a permeable material and an impermeable material.
32. A method in accordance with Claim 30, wherein said step of positioning an end member comprises joining said end member to a length of said tube to form a vessel-shaped member.
33. A method in accordance with Claim 30, wherein said step of positioning a drug core comprises positioning a said drug core in a length of tube which is sized and formed of a material so that said length of tube is dimensionally stable during said positioning.
34. A method in accordance with Claim 32, wherein said joining step comprises abutting said end member against a first end of said length of tube, and leaving a second end of said length of tube uncovered.
35. A method in accordance with Claim 32, wherein said joining step comprises the step of joining an impermeable cap to said length of tube, and wherein said step of forming an outer layer comprises forming an outer layer of a permeable material.
36. A method in accordance with Claim 32, wherein said joining step comprises the step of joining a permeable plug to said length of tube, and wherein said step of forming an outer layer comprises forming an outer layer of an impermeable material.
37. A method in accordance with Claim 36, further comprises the step of:
forming a port in said impermeable outer layer immediately adjacent to said permeable plug.
38. A method in accordance with Claim 37, wherein said step of forming a port further comprises forming a port immediately adjacent to an end surface of said plug opposite said drug core.
39. A method in accordance with Claim 37, wherein said step of forming a port further comprises forming a port immediately adjacent to a radial surface of said plug.
40. A method in accordance with Claim 37, wherein said step of forming a port further comprises forming a plurality of ports.
CA2406277A 2000-04-26 2001-04-19 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof Expired - Lifetime CA2406277C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/558,207 US6375972B1 (en) 2000-04-26 2000-04-26 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US09/558,207 2000-04-26
PCT/US2001/012700 WO2001080825A2 (en) 2000-04-26 2001-04-19 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof

Publications (2)

Publication Number Publication Date
CA2406277A1 true CA2406277A1 (en) 2001-11-01
CA2406277C CA2406277C (en) 2013-06-11

Family

ID=24228594

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2406277A Expired - Lifetime CA2406277C (en) 2000-04-26 2001-04-19 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof

Country Status (24)

Country Link
US (7) US6375972B1 (en)
EP (2) EP1276462B1 (en)
JP (1) JP4705304B2 (en)
KR (1) KR100854541B1 (en)
CN (4) CN106176665A (en)
AR (1) AR028372A1 (en)
AT (1) ATE409023T1 (en)
AU (4) AU2001253675B2 (en)
BR (1) BR0110243A (en)
CA (1) CA2406277C (en)
CY (1) CY1108665T1 (en)
DE (1) DE60135907D1 (en)
DK (1) DK1276462T3 (en)
EA (1) EA004980B1 (en)
ES (1) ES2315282T3 (en)
HK (1) HK1053263B (en)
IL (2) IL152294A0 (en)
MX (1) MXPA02010442A (en)
NZ (2) NZ522002A (en)
PT (1) PT1276462E (en)
SI (1) SI1276462T1 (en)
TW (1) TWI290054B (en)
WO (1) WO2001080825A2 (en)
ZA (1) ZA200208415B (en)

Families Citing this family (280)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2358296A1 (en) * 1999-01-05 2000-07-13 Anthony P. Adamis Targeted transscleral controlled release drug delivery to the retina and choroid
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US8556967B2 (en) 1999-04-09 2013-10-15 Faezeh Mona Sarfarazi Interior bag for a capsular bag and injector
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
US20040175410A1 (en) * 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US20040208910A1 (en) * 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
ATE547080T1 (en) * 2000-08-30 2012-03-15 Univ Johns Hopkins DEVICES FOR INTRAOCULAR DRUG DELIVERY
WO2002056863A2 (en) * 2000-12-29 2002-07-25 Bausch & Lomb Incorporated Sustained release drug delivery devices
US6756058B2 (en) * 2001-01-03 2004-06-29 Bausch & Lomb Incorporated Sustained release drug delivery devices with multiple agents
WO2002053129A1 (en) * 2001-01-03 2002-07-11 Bausch & Lomb Incorporated Sustained release drug delivery devices with prefabricated permeable plugs
US20020148138A1 (en) * 2001-04-06 2002-10-17 Egan Brian A. Smart tread boot covers
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
EP2283845A1 (en) * 2001-04-26 2011-02-16 pSivida Inc. Sustained release drug delivery system containing codrugs
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
JP2004536631A (en) * 2001-05-03 2004-12-09 マサチューセッツ・アイ・アンド・イア・インファーマリー Implantable drug delivery device and use thereof
EP1404297B1 (en) * 2001-06-12 2011-04-27 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
JP2004535431A (en) * 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド Zero-order long-term release coaxial implant
JP4426286B2 (en) * 2001-07-10 2010-03-03 テバ ファーマシューティカル インダストリーズ リミティド Drug delivery system for zero order, zero order-biphasic, ascending or descending drug release
AU2002319606B2 (en) * 2001-07-23 2006-09-14 Alcon, Inc. Ophthalmic drug delivery device
EP1409065B1 (en) 2001-07-23 2007-01-17 Alcon, Inc. Ophthalmic drug delivery device
IN2014DN10834A (en) * 2001-09-17 2015-09-04 Psivida Inc
US20060034929A1 (en) * 2001-12-27 2006-02-16 Brubaker Michael J Sustained release drug delivery devices with prefabricated permeable plugs
US20030229333A1 (en) * 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
MXPA04008903A (en) * 2002-03-11 2004-11-26 Alcon Inc Implantable drug delivery system.
WO2003087367A2 (en) * 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
AU2003217531A1 (en) * 2002-05-02 2003-11-17 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
CA2484632C (en) 2002-05-07 2012-12-11 Control Delivery Systems, Inc. Processes for forming a drug delivery device
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
MXPA04011416A (en) 2002-05-17 2005-09-30 Othera Pharmaceuticals Inc Amelioration of the development of cataracts and other opthalmic diseases.
US6976584B2 (en) 2002-06-26 2005-12-20 Bausch & Lomb Incorporated Package for surgical implant
CN100435880C (en) * 2003-02-28 2008-11-26 微创医疗器械(上海)有限公司 Medicament elution interventional medical apparatus and preparing method thereof
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
AU2003301347A1 (en) * 2002-10-17 2004-05-04 Control Delivery Systems, Inc. Methods for monitoring treatment of disease
CA2510296A1 (en) * 2002-12-20 2004-07-15 Control Delivery Systems, Inc. Steroid compositions for intraocular use
AU2004205895B2 (en) 2003-01-16 2009-02-26 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of ICAM-1
ES2338420T3 (en) * 2003-01-24 2010-05-07 Psivida Us Inc. DEVICE AND PROCEDURE FOR SUSTAINED RELEASE FOR THE OCULAR ADMINISTRATION OF INHIBITORS OF CARBONIC ANHYDRATION.
SI1592408T1 (en) * 2003-01-24 2010-01-29 Psivida Inc Sustained release device and method for ocular delivery of adrenergic agents
AU2004207523A1 (en) * 2003-01-24 2004-08-12 Control Delivery Systems, Inc. Controlled release of highly soluble agents
WO2004066939A2 (en) * 2003-01-27 2004-08-12 Sarnoff Corporation Controlled-release drug delivery system
WO2004073551A2 (en) * 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
US9445901B2 (en) * 2003-03-12 2016-09-20 Deger C. Tunc Prosthesis with sustained release analgesic
US7037521B2 (en) * 2003-03-28 2006-05-02 Bausch & Lomb Incorporated Using a laser for cutting a hole in a capsule for controlled drug delivery
US20050261668A1 (en) * 2003-03-28 2005-11-24 Bausch & Lomb Incorporated Drug delivery device
CA2524271C (en) * 2003-05-02 2012-09-04 Surmodics, Inc. Controlled release bioactive agent delivery device
US8246974B2 (en) * 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
US7589107B2 (en) 2003-05-19 2009-09-15 Othera Holding, Inc. Amelioration of vitrectomy-induced cataracts
US7825134B2 (en) * 2003-05-19 2010-11-02 Othera Holding, Inc. Amelioration of cataracts, macular degeneration and other ophthalmic diseases
ES2315680T3 (en) 2003-06-26 2009-04-01 Psivida Inc. IN SITU GELIFICATION PHARMACY DISTRIBUTION SYSTEM.
ATE536861T1 (en) * 2003-06-26 2011-12-15 Control Delivery Sys Inc BIOERODABLE SUSTAINED RELEASE DRUG DELIVERY SYSTEMS
PT1638535E (en) * 2003-06-26 2007-11-08 Mediolanum Pharmaceuticals Ltd Subcutaneous implants having limited initial release of the active principle and subsequent linearly varying extended release thereof
SI1635787T1 (en) * 2003-06-26 2012-04-30 Psivida Inc Bioerodible sustained release drug delivery systems
US7875272B2 (en) * 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US8790637B2 (en) * 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US8491883B2 (en) * 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
CA2530533C (en) 2003-06-27 2015-02-10 Ethicon, Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US20060223177A1 (en) 2003-06-27 2006-10-05 Ethicon Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US7875273B2 (en) 2004-12-23 2011-01-25 Ethicon, Incorporated Treatment of Parkinson's disease and related disorders using postpartum derived cells
US20040265356A1 (en) * 2003-06-30 2004-12-30 Bausch & Lomb Incorporated Drug delivery device
US20050054586A1 (en) * 2003-06-30 2005-03-10 Bartels Stephen P. Treatment of ophthalmic disorders
ZA200508654B (en) * 2003-07-10 2007-01-31 Alcon Inc Ophthalmic drug delivery device
AU2004274026A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
ATE460901T1 (en) * 2003-11-13 2010-04-15 Psivida Inc SUSTAINED RELEASE INJECTABLE IMPLANT HAVING A BIOERODIBLE MATRIX CORE AND A BIOERODIBLE SKIN
CN1901850B (en) * 2003-11-13 2012-10-03 普西维达公司 Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
US20050130906A1 (en) * 2003-11-20 2005-06-16 Matier William L. Amelioration of macular degeneration and other ophthalmic diseases
US20050148948A1 (en) * 2003-12-19 2005-07-07 Caputa Steven G. Sutureless ophthalmic drug delivery system and method
US7211272B2 (en) 2003-12-22 2007-05-01 Bausch & Lomb Incorporated Drug delivery device
US20050158365A1 (en) * 2003-12-22 2005-07-21 David Watson Drug delivery device with mechanical locking mechanism
US20050137538A1 (en) * 2003-12-22 2005-06-23 Bausch & Lomb Incorporated Drug delivery device
US20050136095A1 (en) * 2003-12-22 2005-06-23 Brian Levy Drug delivery device with suture ring
JP2007519724A (en) * 2004-01-26 2007-07-19 シヴィダ・インコーポレイテッド Controlled and sustained delivery of therapeutic agents based on nucleic acids
US20060018949A1 (en) * 2004-04-07 2006-01-26 Bausch & Lomb Incorporated Injectable biodegradable drug delivery system
US20050232972A1 (en) * 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US9549895B2 (en) * 2004-04-23 2017-01-24 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
ZA200610032B (en) * 2004-05-25 2008-11-26 Othera Holding Inc Oculoselective drugs and prodrugs
US20060024350A1 (en) * 2004-06-24 2006-02-02 Varner Signe E Biodegradable ocular devices, methods and systems
WO2006004795A2 (en) 2004-06-25 2006-01-12 The Johns Hopkins University Angiogenesis inhibitors
US20060110428A1 (en) * 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
AU2005269988B2 (en) * 2004-07-02 2012-02-02 Mati Therapeutics Inc. Treatment medium delivery device and methods for delivery
US7117870B2 (en) * 2004-07-26 2006-10-10 Clarity Corporation Lacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
AU2005325213B2 (en) * 2004-08-04 2010-10-07 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
US8246569B1 (en) 2004-08-17 2012-08-21 California Institute Of Technology Implantable intraocular pressure drain
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
US20060067978A1 (en) * 2004-09-29 2006-03-30 Bausch & Lomb Incorporated Process for preparing poly(vinyl alcohol) drug delivery devices
US20060068012A1 (en) * 2004-09-29 2006-03-30 Bausch & Lomb Incorporated Process for preparing poly (vinyl alcohol) drug delivery devices with humidity control
WO2006039333A1 (en) * 2004-09-30 2006-04-13 Bausch & Lomb Incorporated Ophthalmic drug release device for multiple drug release
WO2006039459A1 (en) * 2004-09-30 2006-04-13 Bausch & Lomb Incorporated Capsule for encasing tablets for surgical insertion into the human body
WO2006057859A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
US20070276481A1 (en) * 2004-12-08 2007-11-29 Renner Steven B Drug delivery device
US20060134162A1 (en) * 2004-12-16 2006-06-22 Larson Christopher W Methods for fabricating a drug delivery device
US20060171930A1 (en) * 2004-12-21 2006-08-03 Agnieszka Seyda Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same
WO2006083394A2 (en) * 2004-12-21 2006-08-10 Ethicon, Inc. Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
US20060153815A1 (en) * 2004-12-21 2006-07-13 Agnieszka Seyda Tissue engineering devices for the repair and regeneration of tissue
US20060134176A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
WO2006068898A1 (en) * 2004-12-22 2006-06-29 Bausch & Lomb Incorporated Reusable drug delivery device
US20060134174A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
KR101387456B1 (en) 2005-02-09 2014-04-21 산텐 세이야꾸 가부시키가이샤 Liquid formulations for treatment of diseases or conditions
WO2006110487A1 (en) * 2005-04-08 2006-10-19 Surmodics, Inc. Sustained release implants for subretinal delivery
US20060258994A1 (en) * 2005-05-12 2006-11-16 Avery Robert L Implantable delivery device for administering pharmacological agents to an internal portion of a body
WO2006127592A2 (en) * 2005-05-26 2006-11-30 Othera Pharmaceuticals, Inc. Use of hydroxylamine derivates for inhibiting vitrectomy-induced cataracts
US20060292202A1 (en) * 2005-06-27 2006-12-28 Bausch & Lomb Incorporated Drug delivery device
CN101600475A (en) 2005-07-27 2009-12-09 佛罗里达大学研究基金会有限公司 Revise the miniaturization compound and the use thereof of protein false folding
US8067189B2 (en) * 2005-09-01 2011-11-29 Bristol-Myers Squibb Company Methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators by measuring the level of collagen type IV
US20070212397A1 (en) * 2005-09-15 2007-09-13 Roth Daniel B Pharmaceutical delivery device and method for providing ocular treatment
US20090136514A1 (en) * 2005-12-07 2009-05-28 Power David F Tetracyclines for Treating Ocular Diseases and Disorders
US9175261B2 (en) * 2005-12-16 2015-11-03 DePuy Synthes Products, Inc. Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation
WO2007076522A2 (en) * 2005-12-28 2007-07-05 Ethicon, Incorporated Treatment of peripheral vascular disease using postpartum-derived cells
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
EP2001438A2 (en) 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
US20070203190A1 (en) * 2006-02-22 2007-08-30 Ghanshyam Patil Hydroxylamines and derivatives for the inhibition of complement activation
EP1998829B1 (en) 2006-03-14 2011-02-09 University Of Southern California Mems device for delivery of therapeutic agents
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
KR20110038144A (en) * 2006-03-31 2011-04-13 큐엘티 플러그 딜리버리, 인코포레이티드 Drug delivery methods, structures, and compositions for nasolacrimal system
US20090130212A1 (en) * 2006-05-15 2009-05-21 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
ES2390499T3 (en) * 2006-06-12 2012-11-13 Opko Pharmaceuticals, Llc Compositions and methods for inhibition of angiogenesis by sirna
US20080045911A1 (en) * 2006-06-21 2008-02-21 Borgia Maureen J Punctal plugs for the delivery of active agents
US9173773B2 (en) * 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US9474645B2 (en) * 2006-06-21 2016-10-25 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US20080086101A1 (en) * 2006-08-25 2008-04-10 David Freilich Ophthalmic insert
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
US20100034808A1 (en) * 2006-11-21 2010-02-11 Toru Nakazawa Compositions and methods for preserving cells of the eye
US20080145405A1 (en) * 2006-12-15 2008-06-19 Kunzler Jay F Drug delivery devices
JP2010514517A (en) * 2006-12-26 2010-05-06 キューエルティー プラグ デリバリー，インク． Drug delivery implants for the suppression of visual defects
CA2679066A1 (en) 2007-02-22 2008-08-28 Othera Holding, Inc. Hydroxylamine compounds and methods of their use
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
CA2698580C (en) 2007-09-07 2016-10-11 Qlt Plug Delivery, Inc. Lacrimal implant detection
CA2698508C (en) 2007-09-07 2017-06-06 Alan R. Rapacki Lacrimal implants and related methods
EP2205192A2 (en) * 2007-09-07 2010-07-14 QLT Plug Delivery, Inc. Insertion and extraction tools for lacrimal implants
KR101996336B1 (en) * 2007-09-07 2019-07-04 마티 테라퓨틱스 인코포레이티드 Drug cores for sustained release of therapeutic agents
US9775882B2 (en) * 2007-09-20 2017-10-03 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
JP5323845B2 (en) * 2007-10-05 2013-10-23 エシコン・インコーポレイテッド Repair and reconstruction of kidney tissue using human umbilical cord tissue-derived cells
JP5330401B2 (en) 2007-11-08 2013-10-30 アリメラ・サイエンシーズ，インコーポレーテッド Implant device for the eye and kit comprising the device
ES2718612T3 (en) 2007-12-20 2019-07-03 Evonik Corp Procedure for preparing microparticles that have a low volume of residual solvent
EP2666510B1 (en) 2007-12-20 2017-10-18 University Of Southern California Apparatus for controlled delivery of therapeutic agents
US20090192493A1 (en) * 2008-01-03 2009-07-30 University Of Southern California Implantable drug-delivery devices, and apparatus and methods for refilling the devices
CN102014816B (en) * 2008-02-18 2015-04-15 马缇医疗股份有限公司 Lacrimal implants and related methods
FR2927798B1 (en) * 2008-02-25 2011-03-04 C L Investissements METHOD FOR MANUFACTURING AN INTRA-UTERIN CONTRACEPTIVE DEVICE AND INSTALLATION FOR IMPLEMENTING SAID METHOD
CA2722002C (en) 2008-04-30 2018-06-19 Qlt Plug Delivery, Inc. Composite lacrimal insert and related methods
US8231609B2 (en) * 2008-05-08 2012-07-31 Minipumps, Llc Drug-delivery pumps and methods of manufacture
CN103394142B (en) 2008-05-08 2015-08-19 迷你泵有限责任公司 Implantable drug delivery devices with for filling equipment and the method for this device
CN104353150A (en) * 2008-05-08 2015-02-18 迷你泵有限责任公司 Implantable pums and cannulas therefor
US9333297B2 (en) 2008-05-08 2016-05-10 Minipumps, Llc Drug-delivery pump with intelligent control
CN105251007A (en) * 2008-05-09 2016-01-20 马缇医疗股份有限公司 Sustained release delivery of active agents to treat glaucoma and ocular hypertension
SG171952A1 (en) 2008-12-04 2011-07-28 Opko Ophthalmics Llc Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
JP6095893B2 (en) * 2008-12-19 2017-03-15 デピュイ・シンセス・プロダクツ・インコーポレイテッド Regeneration and repair of nerve tissue after injury
US10179900B2 (en) * 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
WO2010071864A1 (en) 2008-12-19 2010-06-24 Ethicon, Incorporated Treatment of lung and pulmonary diseases and disorders
EP2379087B1 (en) * 2008-12-19 2014-08-20 DePuy Synthes Products, LLC Umbilical cord tissue derived cells for treating neuropathic pain and spasticity
WO2010071844A1 (en) * 2008-12-19 2010-06-24 Qlt Plug Delivery, Inc Substance delivering punctum implants and methods
PL2391419T3 (en) 2009-01-29 2019-12-31 Forsight Vision4, Inc. Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
WO2010093945A2 (en) 2009-02-13 2010-08-19 Glaukos Corporation Uveoscleral drug delivery implant and methods for implanting the same
CN105997339B (en) * 2009-02-23 2018-09-04 马缇医疗股份有限公司 Lacrimal implants
WO2010105093A2 (en) 2009-03-12 2010-09-16 Delpor, Inc. Implantable device for long-term delivery of drugs
WO2010111627A1 (en) * 2009-03-26 2010-09-30 Psivida Us, Inc. Implantable formulations of bisphosphonic acids
BRPI1013409A2 (en) 2009-03-26 2018-01-16 Advanced Tech And Regenerative Medicine Llc human umbilical cord tissue cells as therapy for alzheimer's disease
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2010135369A1 (en) * 2009-05-18 2010-11-25 Dose Medical Corporation Drug eluting ocular implant
ES2921527T3 (en) 2009-06-03 2022-08-29 Forsight Vision5 Inc Anterior segment drug delivery
IN2012DN00352A (en) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
WO2011008896A2 (en) 2009-07-14 2011-01-20 Board Of Regents, The University Of Texas System Therapeutic methods using controlled delivery devices having zero order kinetics
EP2467797B1 (en) * 2009-08-18 2017-07-19 MiniPumps, LLC Electrolytic drug-delivery pump with adaptive control
US8808257B2 (en) * 2009-08-31 2014-08-19 Johnson & Johnson Vision Care, Inc. Methods and apparatus for pulsatile release of medicaments from a punctal plug
JP2013512677A (en) * 2009-12-04 2013-04-18 オプコ オプサルミクス、エルエルシー Compositions and methods for inhibition of VEGF
US20110238036A1 (en) * 2009-12-23 2011-09-29 Psivida Us, Inc. Sustained release delivery devices
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
JP2013523821A (en) * 2010-04-06 2013-06-17 アラーガン、インコーポレイテッド Sustained release reservoir implant for intra-anterior drug delivery
WO2011133964A2 (en) 2010-04-23 2011-10-27 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
WO2011139594A2 (en) * 2010-04-27 2011-11-10 Medtronic, Inc. Artificial bursa for intra-articular drug delivery
WO2011161666A2 (en) * 2010-06-21 2011-12-29 White Innovation Ltd. Enclosed liquid capsules
EP2585057B1 (en) 2010-06-25 2017-08-23 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Methods of treatment using sterculic acid
JP2012025708A (en) * 2010-07-27 2012-02-09 Sepa Sigma Inc Release-controlled local administration agent using plurality of release control mechanisms different in membrane permeation mechanisms
WO2012019139A1 (en) 2010-08-05 2012-02-09 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
SI2600812T1 (en) 2010-08-05 2021-12-31 ForSight Vision4, Inc., Apparatus to treat an eye
EP3861969A1 (en) 2010-08-05 2021-08-11 ForSight Vision4, Inc. Injector apparatus for drug delivery
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
WO2012061045A2 (en) 2010-11-01 2012-05-10 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving retinal ganglion cells
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US8679093B2 (en) 2010-11-23 2014-03-25 Microchips, Inc. Multi-dose drug delivery device and method
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
WO2012088306A2 (en) * 2010-12-22 2012-06-28 Psivida Us, Inc. Two-piece injectable drug delivery device with heat-cured seal
CA2827082A1 (en) * 2011-02-11 2012-08-16 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics
US9603997B2 (en) 2011-03-14 2017-03-28 Minipumps, Llc Implantable drug pumps and refill devices therefor
US9919099B2 (en) 2011-03-14 2018-03-20 Minipumps, Llc Implantable drug pumps and refill devices therefor
US10286146B2 (en) 2011-03-14 2019-05-14 Minipumps, Llc Implantable drug pumps and refill devices therefor
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
EA032666B1 (en) 2011-06-14 2019-06-28 Бикам Фармасьютикалз, Инк. Opsin-binding ligands and methods of use thereof
US20150005254A1 (en) 2011-06-27 2015-01-01 Massachusetts Eye And Ear Infirmary Methods for treating ocular inflammatory disorders
EP4249059A3 (en) 2011-06-28 2023-11-29 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
US9724357B2 (en) 2011-08-15 2017-08-08 Massachusetts Eye & Ear Infirmary Methods for preserving photoreceptor cell viability following retinal detachment
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
CA2846384C (en) 2011-08-29 2020-12-15 Qlt Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2740680C2 (en) 2011-09-14 2021-01-19 Форсайт Вижн5, Инк. Eye inserter device and methods
SI2755600T1 (en) 2011-09-16 2021-08-31 Forsight Vision4, Inc. Fluid exchange apparatus
CA2850624A1 (en) 2011-10-03 2013-04-11 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CA2888805C (en) 2011-10-21 2020-07-14 Massachusetts Eye And Ear Infirmary Methods and compositions for promoting axon regeneration and nerve function
JP2014534864A (en) 2011-10-28 2014-12-25 プレサージュ バイオサイエンシズ，インコーポレイテッド Drug delivery method
US8685106B2 (en) * 2011-11-15 2014-04-01 Abraham Lin Method of a pharmaceutical delivery system for use within a joint replacement
US9353063B2 (en) 2011-11-30 2016-05-31 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CA2862746A1 (en) 2011-12-01 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
KR20140102759A (en) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 Modified nucleoside, nucleotide, and nucleic acid compositions
BR112014015424A2 (en) 2011-12-23 2018-05-22 Depuy Synthes Products Llc detection of cells derived from human umbilical cord tissue
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US10182932B2 (en) 2012-02-21 2019-01-22 Allurion Technologies, Inc. Methods and devices for deploying and releasing a temporary implant within the body
WO2014074625A1 (en) 2012-02-21 2014-05-15 Allurion Technologies, Inc. Anatomically adapted ingestible delivery systems and methods
US8974483B2 (en) 2012-02-21 2015-03-10 Allurion Technologies, Inc. Methods and devices for deploying and releasing a temporary implant within the body
EP3189817B1 (en) * 2012-02-21 2018-10-17 Allurion Technologies, Inc. Devices for deploying and releasing a temporary implant within the body
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2868398A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
MX351261B (en) 2012-06-01 2017-10-06 Surmodics Inc Apparatus and method for coating balloon catheters.
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
EP2885045A4 (en) * 2012-08-20 2016-07-20 O Ray Pharma Inc Process for manufacturing drug delivery formulations
PT2911623T (en) 2012-10-26 2019-11-21 Forsight Vision5 Inc Ophthalmic system for sustained release of drug to eye
JP6144355B2 (en) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Chemically modified mRNA
EP2968613B1 (en) 2013-03-11 2019-09-11 University of Florida Research Foundation, Inc. Delivery of card protein as therapy for occular inflammation
US20140309610A1 (en) * 2013-03-12 2014-10-16 Psivida Corp. Drug Delivery Device Comprising Silicon-Based Carrier Particles
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
NZ711546A (en) 2013-03-15 2017-12-22 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
EP4302736A3 (en) 2013-03-28 2024-04-03 ForSight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
JP2016538829A (en) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Polynucleotide encoding low density lipoprotein receptor
EP3089748A4 (en) 2014-01-02 2017-09-27 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
AU2015266850B2 (en) * 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10258503B2 (en) 2014-07-15 2019-04-16 Forsight Vision4, Inc. Ocular implant delivery device and method
TW201618783A (en) 2014-08-07 2016-06-01 艾森塔製藥公司 Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on BTK occupancy and BTK resynthesis rate
MY182793A (en) 2014-08-08 2021-02-05 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
CN106687080A (en) * 2014-09-11 2017-05-17 普西维达公司 Injector apparatus
US10507101B2 (en) 2014-10-13 2019-12-17 W. L. Gore & Associates, Inc. Valved conduit
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
EP3285850A1 (en) 2015-04-23 2018-02-28 TARIS Biomedical LLC Drug delivery devices with drug-permeable component and methods
US10669321B2 (en) 2015-06-08 2020-06-02 Retinal Solutions Llc Retinal capillary regeneration with synthetic norrin protein
US10202429B2 (en) 2015-06-08 2019-02-12 Retinal Solutions Llc Norrin regulation of cellular production of junction proteins and use to treat retinal vasculature edema
US10206978B2 (en) 2015-06-08 2019-02-19 Retinal Solutions Llc Norrin regulation of junction proteins and the use thereof to treat epithelial or endothelial membrane leakage induced edema
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US10172740B2 (en) 2015-11-06 2019-01-08 David E Freilich Lacrimal stent
EA038755B1 (en) 2015-11-12 2021-10-14 Грейбаг Вижн, Инк. Aggregating microparticles for providing sustained release of a therapeuic agent for intraocular delivery
CN108430405B (en) 2015-11-20 2021-04-13 弗赛特影像4股份有限公司 Porous structures for sustained release drug delivery devices
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
AU2017252294B2 (en) 2016-04-20 2021-12-02 Dose Medical Corporation Bioresorbable ocular drug delivery device
MA45623A (en) 2016-07-05 2019-05-15 Janssen Biotech Inc TREATMENT OF RETINAL VASCULAR DISEASE USING PROGENITOR CELLS
JP2020514407A (en) 2017-01-24 2020-05-21 マクリーゲン, インク.Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases using apolipoprotein mimetics
WO2018161035A1 (en) 2017-03-03 2018-09-07 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
US11523940B2 (en) 2017-03-17 2022-12-13 W. L. Gore & Associates, Inc. Delivery aids for glaucoma shunts
AU2018240462C1 (en) 2017-03-23 2022-12-08 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
CN111201040A (en) 2017-05-10 2020-05-26 灰色视觉公司 Sustained release microparticles and suspensions thereof for medical therapy
WO2019018350A1 (en) 2017-07-17 2019-01-24 Keith Roizman Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases
US10744313B2 (en) * 2017-07-27 2020-08-18 University Of Utah Research Foundation Therapeutic delivery device
WO2019103906A1 (en) 2017-11-21 2019-05-31 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
EP3755240B1 (en) 2018-02-26 2024-03-27 Allurion Technologies, Inc. Automatic-sealing balloon-filling catheter system
US11690807B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
SG11202005949UA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
US11098813B2 (en) 2018-07-06 2021-08-24 Allurion Technologies, Inc. Binary fluid control valve system
WO2020035819A1 (en) * 2018-08-15 2020-02-20 Microsert Ltd. Sustained release component and corresponding drug delivery device with biodegradable material for flow path modification
CN109172963B (en) * 2018-10-19 2021-05-14 青岛大学附属医院 Atomization physical therapy instrument with continuous administration function
WO2020112816A1 (en) 2018-11-29 2020-06-04 Surmodics, Inc. Apparatus and methods for coating medical devices
US11678983B2 (en) 2018-12-12 2023-06-20 W. L. Gore & Associates, Inc. Implantable component with socket
CN113242723A (en) 2018-12-13 2021-08-10 阿勒里恩科技公司 Enhanced fluid delivery system
US11039954B2 (en) 2019-03-21 2021-06-22 Microoptx Inc. Implantable ocular drug delivery devices and methods
CN110046067B (en) * 2019-04-22 2023-10-31 无线生活（杭州）信息科技有限公司 Interface testing method and device
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
AU2020371620A1 (en) 2019-10-24 2022-03-31 Denis E. Labombard Ocular device and drug delivery system, with case
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416350A (en) 1966-02-23 1968-12-17 Martin Marietta Corp Gripping structure
US3416530A (en) 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3896819A (en) 1969-04-01 1975-07-29 Alejandro Zaffaroni IUD having a replenishing drug reservoir
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3618604A (en) 1969-06-09 1971-11-09 Alza Corp Ocular insert
US3632739A (en) 1969-12-29 1972-01-04 Sandoz Ag Solid sustained release pharmaceutical preparation
US3980463A (en) 1970-11-16 1976-09-14 Sumitomo Chemical Company, Limited Process for producing granular composition for use in agriculture and horticulture
US3829570A (en) * 1971-01-26 1974-08-13 Boehringer Sohn Ingelheim Therapeutic compositions and method
US3993071A (en) 1971-09-09 1976-11-23 Alza Corporation Bioerodible ocular device
US3828777A (en) 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US3948254A (en) * 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3892570A (en) * 1972-04-18 1975-07-01 Xerox Corp Light activating imaging process
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4177256A (en) 1973-04-25 1979-12-04 Alza Corporation Osmotic bursting drug delivery device
US4036227A (en) 1973-04-25 1977-07-19 Alza Corporation Osmotic releasing device having a plurality of release rate patterns
US4351337A (en) 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US3914402A (en) 1973-06-14 1975-10-21 Alza Corp Ophthalmic dosage form, for releasing medication over time
US3961628A (en) 1974-04-10 1976-06-08 Alza Corporation Ocular drug dispensing system
US4096238A (en) 1974-12-23 1978-06-20 Alza Corporation Method for administering drug to the gastrointestinal tract
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4014355A (en) 1975-08-11 1977-03-29 Dynell Electronics Corporation Bidet and hygienic cleansing arrangement
US4034758A (en) 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US3977404A (en) 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4014334A (en) 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4247498A (en) 1976-08-30 1981-01-27 Akzona Incorporated Methods for making microporous products
US4111203A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4111201A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4519909A (en) 1977-07-11 1985-05-28 Akzona Incorporated Microporous products
US4186184A (en) 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
JPS54119021A (en) 1978-03-06 1979-09-14 Nippon Kayaku Co Ltd Carcinostatic agent
US4290426A (en) 1978-05-04 1981-09-22 Alza Corporation Dispenser for dispensing beneficial agent
US4260736A (en) * 1978-08-14 1981-04-07 Kureha Kagaku Kogyo Kabushiki Kaisha Steroid hormone-antitumor derivatives
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4304232A (en) 1979-03-14 1981-12-08 Alza Corporation Unit system having multiplicity of means for dispensing useful agent
US4283394A (en) * 1979-08-06 1981-08-11 Research Corporation Cytotoxic nucleoside-corticosteroid phosphodiesters
US4304765A (en) 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4322323A (en) 1980-12-01 1982-03-30 Alza Corporation Erodible device comprising surfactant for modifying the rate of erosion of the device
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4484922A (en) 1981-06-25 1984-11-27 Rosenwald Peter L Occular device
JPS5835110A (en) 1981-08-28 1983-03-01 Tetsuo Kato Gradually releasing microcapsule
US4730013A (en) 1981-10-08 1988-03-08 Merck & Co., Inc. Biosoluble ocular insert
US4475916A (en) 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
DK90883A (en) 1982-03-18 1983-09-19 Merck & Co Inc CONTAINER FOR OSMOTIC RELEASE OF A SUBSTANCE OR MIXTURE
US4432965A (en) 1982-07-09 1984-02-21 Key Pharmaceuticals, Inc. Quinidine sustained release dosage formulation
US4519801A (en) 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4522625A (en) 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
US4478818A (en) 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US4673405A (en) 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
JPS60100516A (en) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
US4777049A (en) 1983-12-01 1988-10-11 Alza Corporation Constant release system with pulsed release
EP0147780A3 (en) 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
IT1206166B (en) 1984-07-26 1989-04-14 Sigma Tau Ind Farmaceuti DEVICE FOR RELEASING A SUBSTANCE IN A DISSOLUTION FLUID WITH ZERO ORDER KINETICS AND PROCEDURE FOR ITS PREPARATION
US4692336A (en) 1984-03-19 1987-09-08 Alza Corporation Self controlled release device for administering beneficial agent to recipient
US4716031A (en) 1984-03-21 1987-12-29 Alza Corporation Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug
US4615698A (en) 1984-03-23 1986-10-07 Alza Corporation Total agent osmotic delivery system
EP0159604B1 (en) 1984-04-09 1990-11-07 Toyo Boseki Kabushiki Kaisha Sustained-release preparation applicable to mucous membrane in oral cavity
US4657543A (en) 1984-07-23 1987-04-14 Massachusetts Institute Of Technology Ultrasonically modulated polymeric devices for delivering compositions
US4743247A (en) 1984-08-13 1988-05-10 Alza Corporation Process for manufacturing dosage form
US4927687A (en) 1984-10-01 1990-05-22 Biotek, Inc. Sustained release transdermal drug delivery composition
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4863735A (en) 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
US4913906B1 (en) 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
US4693886A (en) 1985-04-22 1987-09-15 Alza Corporation Osmotic device with inert core
US4624847A (en) 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US4609374A (en) 1985-04-22 1986-09-02 Alza Corporation Osmotic device comprising means for governing initial time of agent release therefrom
US4720384A (en) 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
JPS6210381A (en) 1985-07-08 1987-01-19 大成建設株式会社 Film surface connector in pneumatic film structure
US4898733A (en) 1985-11-04 1990-02-06 International Minerals & Chemical Corp. Layered, compression molded device for the sustained release of a beneficial agent
US4717567A (en) 1985-11-25 1988-01-05 Eastman Kodak Company Rumen-stable pellets
IT1188212B (en) 1985-12-20 1988-01-07 Paolo Colombo SYSTEM FOR THE RELEASE SPEED OF ACTIVE SUBSTANCES
US4764364A (en) 1986-02-25 1988-08-16 S R I International Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product
US4814323A (en) 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
AU605482B2 (en) * 1986-04-17 1991-01-17 Castex Products Limited Pellet for administration to ruminants
US5141752A (en) 1986-05-09 1992-08-25 Alza Corporation Delayed drug delivery device
US5342622A (en) 1986-05-16 1994-08-30 The State Of Victoria Subdermal biocompatible implants
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4786500A (en) 1986-06-26 1988-11-22 Alza Corporation Programmable agent delivery system
US4927632A (en) 1986-06-26 1990-05-22 Alza Corporation Selective pulsed drug delivery system
JPH0794384B2 (en) 1986-09-01 1995-10-11 帝国製薬株式会社 Sustained-release oral formulation
US5147647A (en) 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US4830860A (en) 1986-10-30 1989-05-16 Pfizer Inc. Stressed polymeric device for controlled release of a substance to an ambient environment
NL194638C (en) 1986-12-19 2002-10-04 Novartis Ag Hydrosol containing solid particles of a pharmaceutically active substance and pharmaceutical preparation containing this hydrosol.
US4806382A (en) 1987-04-10 1989-02-21 University Of Florida Ocular implants and methods for their manufacture
US4861627A (en) 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US4789513A (en) 1987-06-05 1988-12-06 P.C.E. Corp. Coextrusion apparatus and process
DE19975054I2 (en) 1987-08-08 2000-04-13 Akzo Nobel Nv Contraceptive implant
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
EP0391909B1 (en) 1987-09-03 1994-08-17 The University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
US4891223A (en) 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
US5035891A (en) * 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
SE8703881D0 (en) 1987-10-08 1987-10-08 Haessle Ab NEW PHARMACEUTICAL PREPARATION
US4994273A (en) 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
IT1223150B (en) 1987-11-18 1990-09-12 Ubaldo Conte TABLET FOR OPHTHALMIC USE AND CONTROLLED RELEASE OF THE ACTIVE SUBSTANCE
US4945089A (en) * 1987-12-29 1990-07-31 Alcon Laboratories, Inc. Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids
US4877618A (en) 1988-03-18 1989-10-31 Reed Jr Fred D Transdermal drug delivery device
AU3432689A (en) * 1988-03-24 1989-10-16 Bukh Meditec A/S Controlled release composition
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US4865846A (en) 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US4946456A (en) * 1988-08-26 1990-08-07 Alza Corp. Fluid imbibing pump activated by capillary action of a fabric or polymeric sleeve
US5124392A (en) 1988-10-03 1992-06-23 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation
US5360611A (en) 1988-10-03 1994-11-01 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
US5306500A (en) 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5174999A (en) 1988-12-13 1992-12-29 Alza Corporation Delivery system comprising fluid ingress and drug egress
DD295760A5 (en) 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De DRUG DISTRIBUTION SYSTEM WITH COTROLLED ACTIVE INGREDIENT TRANSFER
US5098443A (en) 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
FR2645029B1 (en) 1989-03-28 1997-09-12 Cordis Sa IMPLANTABLE TANK MEMBRANE UNDER THE SKIN OF A PATIENT
US5028435A (en) 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
DK469989D0 (en) * 1989-09-22 1989-09-22 Bukh Meditec PHARMACEUTICAL PREPARATION
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5294604A (en) 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
EP0514406B1 (en) 1990-01-30 1994-03-02 Akzo Nobel N.V. Article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances
US5201764A (en) 1990-02-28 1993-04-13 Autogenesis Technologies, Inc. Biologically compatible collagenous reaction product and articles useful as medical implants produced therefrom
US5178866A (en) 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5156623A (en) 1990-04-16 1992-10-20 Olympus Optical Co., Ltd. Sustained release material and method of manufacturing the same
US5091185A (en) 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
GR1001529B (en) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Process for the obtainment of a new pregna-1,4-diene-3,20-dione -16-17-acetal-21 esters
ATE106015T1 (en) 1990-09-28 1994-06-15 Pfizer METER DELIVERY DEVICE CONTAINING A HYDROPHOBIC AGENT.
IS3778A7 (en) 1990-10-31 1992-05-02 Amgen Inc. A method for administering animal growth hormone, where the given amount is controlled
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
NZ242065A (en) 1991-03-26 1996-06-25 Csl Ltd Delayed release implant having a degradable or rupturable polymeric coating
US5226902A (en) 1991-07-30 1993-07-13 University Of Utah Pulsatile drug delivery device using stimuli sensitive hydrogel
AU667681B2 (en) 1991-08-23 1996-04-04 Gillette Company, The Sustained-release martrices for dental application
FR2682090B1 (en) 1991-10-03 1993-12-31 Holzstoff Holding Sa RESERVOIR SYSTEM FOR EXTENDED BROADCASTING OF AN ACTIVE INGREDIENT.
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5512293A (en) * 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
US5314419A (en) * 1992-10-30 1994-05-24 Pelling George E Method for dispensing ophthalmic drugs to the eye
US5840881A (en) * 1992-11-27 1998-11-24 Takeda Chemical Industries, Ltd. Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
US5538735A (en) 1993-02-19 1996-07-23 Ahn; Sam S. Method of making a drug delivery system using hollow fibers
US5393536A (en) 1993-04-05 1995-02-28 Crane Plastics Company Coextrusion apparatus
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
JPH0748246A (en) 1993-08-06 1995-02-21 Fujisawa Pharmaceut Co Ltd Sustained release injection agent
CA2169292C (en) 1993-08-12 2010-11-23 E. Edward Baetge Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
JP3720386B2 (en) * 1993-12-27 2005-11-24 住友製薬株式会社 Drug release controlled formulation
CA2182228C (en) 1994-01-28 2008-09-16 Paul Ashton Codrugs as a method of controlled drug delivery
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
CA2193806A1 (en) 1994-06-22 1995-12-28 Michael Cardamone Controlled release device and method
US5435998A (en) 1994-08-03 1995-07-25 Abelson; Mark B. Treatment of low-tension glaucoma by topical administration of calcium channel blocking agents
KR100201352B1 (en) 1995-03-16 1999-06-15 성재갑 Single shot vaccine formulation
US5569429A (en) 1995-05-05 1996-10-29 Randcastle Extrusion Systems, Inc. Dynamic seal and sealing method
US5554187A (en) 1995-08-18 1996-09-10 Rizzo, Iii; Joseph Medication dispensing intra-ocular lens system
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6283951B1 (en) 1996-10-11 2001-09-04 Transvascular, Inc. Systems and methods for delivering drugs to selected locations within the body
US6039975A (en) * 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
DE19539361A1 (en) 1995-10-23 1997-04-24 Basf Ag Process for the preparation of multilayer, solid pharmaceutical forms for oral or rectal administration
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5797898A (en) * 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
ZA981610B (en) * 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
DK0973499T3 (en) * 1997-03-31 2003-11-17 Alza Corp Implantable diffusion delivery system
IL123813A0 (en) * 1997-04-11 1998-10-30 Akzo Nobel Nv Drug delivery system for two or more active substances
FR2766088B1 (en) 1997-07-17 2001-01-05 Dow Corning Sa DEVICES FOR CONTROLLED RELEASE OF A PHARMACEUTICAL AGENT, THEIR MANUFACTURE BY CO-EXTRUSION AND INTERMEDIATE ARTICLE
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
JP3240593B2 (en) 1998-02-16 2001-12-17 株式会社高研 Pharmaceutical sustained-release agent using soluble collagen powder as carrier
US6267154B1 (en) 1998-06-05 2001-07-31 Abbott Laboratories System for storing mixing and administering a drug
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6368658B1 (en) 1999-04-19 2002-04-09 Scimed Life Systems, Inc. Coating medical devices using air suspension
US6606992B1 (en) 1999-06-30 2003-08-19 Nektar Therapeutics Systems and methods for aerosolizing pharmaceutical formulations
US20030105121A1 (en) 1999-07-27 2003-06-05 Bernard Bihari Method of preventing lipodystrophy syndrome or reversing a pre-existing syndrome in HIV-infected patients being treated with antiretroviral agents
US6491683B1 (en) * 1999-09-07 2002-12-10 Alza Corporation Osmotic dosage form composed of an extruded polymer tube form
US6267058B1 (en) * 1999-10-01 2001-07-31 Flight Rail Corporation Coupling mechanism for magnetically coupled transportation module
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
CA2544460C (en) 1999-10-22 2009-04-07 Allergan, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
KR100416242B1 (en) 1999-12-22 2004-01-31 주식회사 삼양사 Liquid composition of biodegradable block copolymer for drug delivery and process for the preparation thereof
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US20040115268A1 (en) 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
US6242058B1 (en) 2000-05-12 2001-06-05 Dow Corning Corporation Method for forming coatings from radiation curable compositions containing alkenyl ether functional polyisobutylenes
WO2002005788A1 (en) 2000-07-14 2002-01-24 Universiteit Gent Composite solid shaped articles for the controlled delivery of biologically active ingredients
ATE293439T1 (en) 2000-12-07 2005-05-15 Warner Lambert Co METHOD AND SYSTEM FOR EVEN DELIVERY OF DRUGS
EP2283845A1 (en) 2001-04-26 2011-02-16 pSivida Inc. Sustained release drug delivery system containing codrugs
JP2004536631A (en) 2001-05-03 2004-12-09 マサチューセッツ・アイ・アンド・イア・インファーマリー Implantable drug delivery device and use thereof
JP2004535431A (en) 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド Zero-order long-term release coaxial implant
AUPR602401A0 (en) 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
WO2003051328A1 (en) 2001-12-18 2003-06-26 Novo Nordisk A/S Solid dose micro implant
WO2003092615A2 (en) 2002-05-01 2003-11-13 Beth Israel Deaconess Medical Center Use of anti-cd1 antibodies for the modulation of immune responses
CA2484632C (en) 2002-05-07 2012-12-11 Control Delivery Systems, Inc. Processes for forming a drug delivery device
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
WO2004043435A2 (en) 2002-11-13 2004-05-27 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
ATE460901T1 (en) 2003-11-13 2010-04-15 Psivida Inc SUSTAINED RELEASE INJECTABLE IMPLANT HAVING A BIOERODIBLE MATRIX CORE AND A BIOERODIBLE SKIN
JP2007519724A (en) 2004-01-26 2007-07-19 シヴィダ・インコーポレイテッド Controlled and sustained delivery of therapeutic agents based on nucleic acids
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
KR101430760B1 (en) 2005-10-18 2014-08-19 알러간, 인코포레이티드 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
EP2091482A2 (en) 2006-12-01 2009-08-26 Allergan, Inc. Method for determining optimum intraocular locations for drug delivery systems
CN102781452B (en) 2009-12-23 2014-05-28 阿利梅拉科学公司 Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids

Also Published As

Publication number Publication date
US8574613B2 (en) 2013-11-05
DE60135907D1 (en) 2008-11-06
US20050186279A1 (en) 2005-08-25
JP2003530964A (en) 2003-10-21
ZA200208415B (en) 2003-10-17
AU2006202338A1 (en) 2006-06-22
NZ531721A (en) 2005-11-25
CN106176665A (en) 2016-12-07
EA200201140A1 (en) 2003-02-27
US20100119694A1 (en) 2010-05-13
CA2406277C (en) 2013-06-11
US20160038412A1 (en) 2016-02-11
MXPA02010442A (en) 2004-09-06
US20100119580A1 (en) 2010-05-13
IL152294A (en) 2013-04-30
EP1982701A2 (en) 2008-10-22
EP1982701A3 (en) 2009-07-15
AU2001253675B2 (en) 2006-03-02
TWI290054B (en) 2007-11-21
CN101396335A (en) 2009-04-01
US6375972B1 (en) 2002-04-23
CY1108665T1 (en) 2014-04-09
KR100854541B1 (en) 2008-08-26
AR028372A1 (en) 2003-05-07
DK1276462T3 (en) 2009-02-09
AU5367501A (en) 2001-11-07
US9192579B2 (en) 2015-11-24
PT1276462E (en) 2009-01-08
AU2008261114A1 (en) 2009-01-15
EP1276462A2 (en) 2003-01-22
BR0110243A (en) 2003-01-07
US20020102307A1 (en) 2002-08-01
WO2001080825A3 (en) 2002-06-20
EP1276462B1 (en) 2008-09-24
US8574659B2 (en) 2013-11-05
US9849085B2 (en) 2017-12-26
KR20030009447A (en) 2003-01-29
JP4705304B2 (en) 2011-06-22
AU2008261114B2 (en) 2011-06-30
CN101513386A (en) 2009-08-26
CN1438873A (en) 2003-08-27
US20140107594A1 (en) 2014-04-17
EA004980B1 (en) 2004-10-28
NZ522002A (en) 2004-06-25
ES2315282T3 (en) 2009-04-01
WO2001080825A2 (en) 2001-11-01
ATE409023T1 (en) 2008-10-15
IL152294A0 (en) 2003-05-29
SI1276462T1 (en) 2009-02-28
HK1053263B (en) 2009-05-29
AU2006202338B2 (en) 2008-09-18
HK1053263A1 (en) 2003-10-17

Similar Documents

Publication Publication Date Title
CA2406277A1 (en) Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US20190216727A1 (en) Punctal Plug With Active Agent
ES2390991T3 (en) Puncture plugs and therapeutic agent administration procedures
US20040121014A1 (en) Method for treating and/or preventing retinal diseases with sustained release corticosteroids
CA2230947A1 (en) Implantable controlled release device to deliver drugs directly to an internal portion of the body
AR039131A2 (en) METHOD FOR ADMINISTRATING A PHARMACEUTICALLY ACTIVE AGENT TO A TISSUE TO BE TREATED IN A BODY AND METHOD FOR MANAGING A PHARMACEUTICALLY ACTIVE AGENT TO AN EYE
DK0862396T3 (en) Insertable intravaginal rings containing drug
ATE285228T1 (en) DRUG ADMINISTRATION SYSTEM FOR DELAYED, COMPLETE RELEASE OF ACTIVE INGREDIENTS IN THE DIGESTIVE TRACT
YU11100A (en) Sustained release drug delivery devices
WO2000062760A1 (en) Ophthalmic insert and method for sustained release of medication to the eye
CA2104699A1 (en) Sustained release drug delivery devices
AU2001253675A1 (en) Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
KR101969594B1 (en) Implant for intraocular drug delivery
EP0018097A2 (en) Medicated device for controlled drug release
US20190365644A1 (en) Drug delivery system

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210419

MKEX Expiry

Effective date: 20210419